[go: up one dir, main page]

ZA200109331B - Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia. - Google Patents

Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia.

Info

Publication number
ZA200109331B
ZA200109331B ZA200109331A ZA200109331A ZA200109331B ZA 200109331 B ZA200109331 B ZA 200109331B ZA 200109331 A ZA200109331 A ZA 200109331A ZA 200109331 A ZA200109331 A ZA 200109331A ZA 200109331 B ZA200109331 B ZA 200109331B
Authority
ZA
South Africa
Prior art keywords
treatment
senile dementia
glycosaminoglycans
molecular weight
average molecular
Prior art date
Application number
ZA200109331A
Other languages
English (en)
Inventor
Luigi De Ambrosi
Israel Hanin
Jawed Fareed
John Lee
Stanley Lorens
Ronald F Mervis
Umberto Cornelli
Original Assignee
Umberto Cornelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umberto Cornelli filed Critical Umberto Cornelli
Publication of ZA200109331B publication Critical patent/ZA200109331B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
ZA200109331A 1999-05-14 2001-11-13 Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia. ZA200109331B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile

Publications (1)

Publication Number Publication Date
ZA200109331B true ZA200109331B (en) 2002-08-28

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109331A ZA200109331B (en) 1999-05-14 2001-11-13 Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia.

Country Status (22)

Country Link
US (1) US6979680B1 (da)
EP (1) EP1181024B1 (da)
JP (1) JP2002544233A (da)
KR (1) KR100711142B1 (da)
CN (1) CN1178667C (da)
AT (1) ATE288761T1 (da)
AU (1) AU764743C (da)
CA (1) CA2373975A1 (da)
CZ (1) CZ20014092A3 (da)
DE (1) DE60018061T2 (da)
DK (1) DK1181024T3 (da)
ES (1) ES2237425T3 (da)
HK (1) HK1039903B (da)
HU (1) HUP0201100A3 (da)
IL (1) IL146458A0 (da)
IT (1) IT1312107B1 (da)
NO (1) NO328902B1 (da)
PL (1) PL198016B1 (da)
PT (1) PT1181024E (da)
RU (1) RU2248800C2 (da)
WO (1) WO2000069444A1 (da)
ZA (1) ZA200109331B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
AU2006342958A1 (en) 2005-12-22 2007-11-08 Bellus Health (International) Limited Treatment of renal disorders, diabetic nephropathy and dyslipidemias
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
CA2725498C (en) 2008-05-22 2015-06-30 Vladimir Yegorovich Balakin Multi-field charged particle cancer therapy method and apparatus
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
CN102113419B (zh) 2008-05-22 2015-09-02 弗拉迪米尔·叶戈罗维奇·巴拉金 多轴带电粒子癌症治疗方法和装置
US8841866B2 (en) 2008-05-22 2014-09-23 Vladimir Yegorovich Balakin Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system
EP2283711B1 (en) 2008-05-22 2018-07-11 Vladimir Yegorovich Balakin Charged particle beam acceleration apparatus as part of a charged particle cancer therapy system
JP2012519532A (ja) 2009-03-04 2012-08-30 ザクリトエ アクツィアニェールナエ オーブシチェストヴォ プロトム 多方向荷電粒子線癌治療方法及び装置
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2766495B1 (en) * 2011-10-14 2018-04-04 Centre National De La Recherche Scientifique Method of diagnosis, prognostic or treatment of neurodegenerative diseases
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
US4769696A (en) * 1986-05-01 1988-09-06 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1240615B (it) 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale

Also Published As

Publication number Publication date
HK1039903A1 (en) 2002-05-17
AU4405200A (en) 2000-12-05
HUP0201100A2 (hu) 2002-07-29
NO328902B1 (no) 2010-06-14
KR100711142B1 (ko) 2007-04-24
NO20015544L (no) 2002-01-14
KR20020005033A (ko) 2002-01-16
AU764743C (en) 2004-03-18
DK1181024T3 (da) 2005-06-13
HK1039903B (zh) 2005-08-26
CN1178667C (zh) 2004-12-08
ITMI991066A1 (it) 2000-11-14
DE60018061T2 (de) 2006-04-13
AU764743B2 (en) 2003-08-28
IL146458A0 (en) 2002-07-25
WO2000069444A1 (en) 2000-11-23
ATE288761T1 (de) 2005-02-15
CN1350459A (zh) 2002-05-22
CZ20014092A3 (cs) 2002-04-17
EP1181024A1 (en) 2002-02-27
RU2248800C2 (ru) 2005-03-27
HUP0201100A3 (en) 2003-03-28
PT1181024E (pt) 2005-06-30
US6979680B1 (en) 2005-12-27
IT1312107B1 (it) 2002-04-04
PL352070A1 (en) 2003-07-28
EP1181024B1 (en) 2005-02-09
ES2237425T3 (es) 2005-08-01
CA2373975A1 (en) 2000-11-23
PL198016B1 (pl) 2008-05-30
JP2002544233A (ja) 2002-12-24
DE60018061D1 (de) 2005-03-17
NO20015544D0 (no) 2001-11-13

Similar Documents

Publication Publication Date Title
IL146458A0 (en) Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
AU2365701A (en) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
CA2233315A1 (en) Pharmaceutical compositions containing hydroximic acid derivatives
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
AU3083899A (en) (in vitro) formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
PL346143A1 (en) Tan-1057 derivatives
UA42731C2 (uk) Арилалкілтіадіазинони, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб лікування
HK61897A (en) New derivatives of physostigmine their use and pharmaceutical formulations containing them
WO2001083449A3 (en) Rigid pyrrolidone modulators of pkc
AU2001294310A1 (en) Benzopyranyl heterocycle derivatives, process for preparation thereof, and pharmaceutical compositions containing them
WO1999021005A3 (en) Pharmaceutical grade st. john's wort
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders
AU5768298A (en) Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
MX9603713A (es) Composicion farmaceutica sublingual o bucal.
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.